Cart 0

Thrivous Launches Alpha, the Extended Daily Nootropic

Thrivous Administrator Nootropics Product Announcement



Alpha, Extended Daily Nootropic

Orem UT – Thrivous, a human enhancement company, has developed and brought to market Alpha, the extended daily nootropic. Alpha is designed for daily use to support long-term brain function. It is also designed to complement Clarity, Serenity, and Surge, nootropics previously developed and brought to market by Thrivous.

"Alpha is an investment in healthy cognitive aging," said Lincoln Cannon, CEO at Thrivous. "Experience and science have helped us understand that there are several things we can do to 'extend the warranty' on our brains. Regular exercise, sufficient sleep, and stress management can all help. And of course a healthy diet with the right nutrients can help. That's where Alpha comes in. We've done our homework. Alpha combines what we believe, based on a broad review of clinical studies, to be the most well-researched and complementary nutrients for long-term brain function."

Guided by science, Thrivous identifies nootropics and geroprotectors with the greatest potential to support healthy cognitive aging beyond what can be achieved through traditional lifestyle choices alone. Alpha contains ingredients at concentrations and amounts based on high levels of evidence for notable effect from peer-reviewed, double-blind, placebo-controlled studies on humans.

Thrivous makes Alpha from substances in the human diet, including amino acid derivatives, fatty acids, and herbs. It does not contain substances derived from animals. All ingredients and capsules are vegan. Ingredients include Acetyl-L-Carnitine, Alpha-GPC, Alpha-Lipoic Acid, and Ginkgo Biloba. Acetyl-L-Carnitine is an amino acid derivative. Supplementation may decrease ammonia to detoxify the brain. Alpha-GPC is a fatty acid produced naturally in the brain. Supplementation may support long-term brain function. Alpha-Lipoic Acid is a fatty acid. Supplementation may improve the effect of Acetyl-L-Carnitine. And Ginkgo Biloba is an ancient tree with fossils dating back 270 million years. Supplementation may support long-term brain function.

Thrivous publishes the Alpha formula openly and completely, and strives to improve the formula continuously. This contrasts sharply with the practices of many vendors, who hide their product formulas behind proprietary blends. The open-source formula identifies all ingredients and their dosages, which is the only way for consumers to know what and how much they are using, so that they may make good decisions. Because science is never finished, Thrivous continuously monitors and reviews new studies, consults with its advisor board of physicians and scientists, and updates the Alpha formula accordingly.

Thrivous publishes a certificate of analysis and quality for Alpha, sharing all test results from suppliers and manufacturers. This is exceptional among vendors, who often withhold test results or make them difficult to find. Suppliers subject each ingredient to stringent quality testing, including identity, potency, microbial, heavy metals, and other testing as appropriate prior to release for manufacturing. Manufacturers follow strict GMP regulation from the FDA in audited and certified facilities. They monitor production and test finished product to ensure quality prior to release for shipping.

Statements in this press release have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a physician before and during use.

Product Webpage

https://thrivous.com/products/alpha-extended-daily-nootropic

Certificate of Analysis and Quality

https://cloud.thrivous.com/downloads/alpha-coaq-formula-1-20170119.pdf

Related Studies

  1. Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. In 2016, this meta-analysis found that Ginkgo "is potentially beneficial for the improvement of cognitive function, activities of daily living, and global clinical assessment in patients with mild cognitive impairment or Alzheimer's disease".

  2. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. In 2015, this meta-analysis found that Ginkgo "is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms". Regarding some previous studies that found Ginkgo ineffective in the short-term, this study observed that "due to the particularly long pre-dementia phase, expecting a preventive effect of Ginkgo biloba on the incidence of dementia over a period of 3–6 years may be overoptimistic".

  3. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. In 2015, this meta-analysis found that "taking [Ginkgo] is effective and safe in the treatment of dementia". Regarding a previous study that found Ginkgo ineffective in the short-term, this study observed that "another alternative interpretation of [its] negative results might be that [Ginkgo] is no longer effective once the neurodegenerative process of dementia is too advanced. In this case, dementia outcome over a relatively short follow-up would not be the most relevant outcome to assess the efficacy of [Ginkgo] on cognitive aging".

  4. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. In 2014, this study found that Ginkgo "improved [neuropsychiatric symptoms] and cognitive performance in patients with [mild cognitive impairment]. The drug was safe and well tolerated".

  5. Ginkgo Biloba Extract and Long-Term Cognitive Decline: A 20-Year Follow-Up Population-Based Study. In 2013, this 20-year cohort study observed that "cognitive decline in a non-demented elderly population was lower in subjects who reported using Ginkgo than in those who did not".

  6. Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia. In 2012, this study found that Ginkgo "can improve the therapeutic efficacy as well improve cognitive ability and cerebral blood flow supply of patients with vascular cognitive impairment of none dementia (VCIND)".

  7. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. In 2012, this study found that "treatment with [Ginkgo] was safe and resulted in a significant and clinically relevant improvement in cognition, psychopathology, functional measures and quality of life of patients and caregivers".

  8. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. In 2012, this study found that Ginkgo "improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia".

  9. Acetyl-L-carnitine Improves Cognitive Functions In Severe Hepatic Encephalopathy: A Randomized And Controlled Clinical Trial. In 2011, this study found that "the improvement of cognitive deficits, the reduction of ammonia, and the modification of EEG in patients treated with [Acetyl-L-Carnitine] suggest that [Acetyl-L-Carnitine] could represent a new tool in the treatment of severe hepatic encephalopathy".

  10. Oral Acetyl-L-carnitine Therapy Reduces Fatigue In Overt Hepatic Encephalopathy: A Randomized, Double-blind, Placebo-controlled Study. In 2011, this study found that "patients with [Hepatic Encephalopathy] treated with [Acetyl-L-Carnitine] showed a decrease in the severity of both mental and physical fatigue and an increase in physical activity".

  11. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. In 2011, this study found that "Carnitine and [Alpha-Lipoic Acid] prevent lipotoxicity".

  12. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. In 2011, this study found that Acetyl-L-Carnitine "treatment is associated with significant improvement in patient energy levels, general functioning and well-being [and] the improvement of quality of life is associated with reduction of anxiety and depression".

  13. The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain: effect on health-related quality of life. In 2009, this study found that "Oral treatment with alpha-lipoic acid (ALA) and gamma-linolenic acid (GLA) for six weeks in synergy with rehabilitation therapy improved neuropathic symptoms and deficits in patients with radicular neuropathy".

  14. Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders. In 2009, this study found that "marked and moderate improvement of cognitive functions was found in patients of the [Alpha-GPC] group compared to the control one ... Deterioration of cognitive functions was seen less often in the [Alpha-GPC] group than in the control group".

  15. Carbohydrate, Protein, And Fat Metabolism During Exercise After Oral Carnitine Supplementation In Humans. In 2008, this study found that Acetyl-L-Carnitine "supplementation might have the potential to reduce the metabolic stress of exercise or alter ammonia production or removal".

  16. Acetyl-L-carnitine Treatment In Minimal Hepatic Encephalopathy. In 2008, this study found that "the benefits of [Acetyl-L-Carnitine] in comparison with placebo are demonstrated in greater reductions in serum ammonia levels, as well as in improvements of neuropsychological functioning".

  17. R-alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes. In 2008, this study found that "the combination of [Alpha-Lipoic Acid] and [Acetyl-L-Carnitine] may act as PPARG/A dual ligands to complementarily promote mitochondrial synthesis and adipocyte metabolism".

  18. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. In 2007, this study found that "the data add further evidence on the safety and efficacy of [Ginkgo] in the treatment of cognitive and non-cognitive symptoms of dementia".

  19. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. In 2007, this study found that Alpha-Lipoic Acid "appears to improve neuropathic symptoms and deficits".

  20. A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. In 2004, this study found that Ginkgo "might be helpful in treating the early stages of primary degenerative dementia".

  21. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. In 2003, this study found "the clinical usefulness and tolerability of [Alpha-GPC] in the treatment of the cognitive symptoms of dementia disorders of the Alzheimer type."

  22. Carnitine and Choline Supplementation with Exercise Alter Carnitine Profiles, Biochemical Markers of Fat Metabolism and Serum Leptin Concentration in Healthy Women. In 2003, this study found that "choline-induced decrease in serum and urinary carnitine is buffered by carnitine preloading".

  23. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. In 2002, this study found that "feeding [Acetyle-L-Carnitine] in combination with [Alpha-Lipoic Acid] increased metabolism and lowered oxidative stress more than either compound alone".

  24. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. In 2001, this study found "clear internal consistency of clinical data gathered by different experimental situations on the drug effect, especially with regard to the cognitive symptoms (memory, attention) characterising the clinical picture of adult-onset dementia disorders".

About Thrivous

Thrivous is a human enhancement company. Its mission is to help people access technology with the greatest potential to improve their brains and bodies. In pursuit of that mission, it develops and distributes nootropics, including Clarity, the daily nootropic to improve focus, memory, and mood, and to support brain function. For more information, please contact support@thrivous.com.



Older Post Newer Post